Effects of XXXX on mood, @entity4 , and ecchymosis in facial plastic surgery.

@entity1 @entity4 @entity229 @entity134 @entity230
OBJECTIVE: To examine the effects of oral postoperative @entity134 therapy in facial plastic surgery on mood, @entity4 , and ecchymosis. DESIGN: Double-blind randomized trial with placebo control. SETTING: Private practice, ambulatory care facility. @entity1 : Any @entity1 who was to undergo a procedure in which we had previously been employing postoperative @entity134 therapy was a potential @entity1 . Any @entity1 with known contraindications to @entity134 use was excluded. A consecutive, volunteer sample of 60 of 65 @entity1 approached agreed to participate. Five @entity1 of the 60 who participated were excluded from the final results owing to either study or @entity1 errors, leaving a total sample of 55 @entity1 . All 55 @entity1 completed the study in the 7-day follow-up period. No @entity1 were withdrawn owing to adverse effects. INTERVENTION: Taper of @entity229 therapy from 60 mg orally and decreasing by 10 mg each day over a total of 6 days. MAIN OUTCOME MEASURES: Mood, @entity4 , and ecchymosis. RESULTS: No significant differences were noted in mood, @entity4 , or ecchymosis between the placebo and intervention groups. The study observer was blinded to @entity1 groupings in the subjective measures of @entity4 and ecchymosis. The @entity1 rated any changes in mood and were also blinded to the group in which they belonged. CONCLUSIONS: The use of oral @entity230 given postoperatively in facial plastic surgery may be unnecessary and may subject the @entity1 to undue risk. Further studies would be helpful to determine the potential benefit of @entity230 given in different dosages, routes, and timing in relation to the procedure.
